This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
526
Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
Vehicle (placebo) once daily for 48 weeks
Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
Dr. Fred D. Youngswick
Novato, California, United States
Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks
Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.
Time frame: 52 weeks
Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks
Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.
Time frame: 52 weeks
Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks
Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if: * If mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise
Time frame: 52 weeks
Safety and Tolerability Assessed by the Number of Participants With Adverse Events
Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Vehicle (placebo) once daily for 24 weeks
Dr. Larry Doehring
Northglenn, Colorado, United States
Dr. Robert P. Dunne
Melbourne, Florida, United States
Dr. Mark Ling
Newnan, Georgia, United States
Dr. Jesse Plasencia
Chicago, Illinois, United States
Dr. John Mallory
Overland Park, Kansas, United States
Dr. Jeffrey Conrow
Topeka, Kansas, United States
Dr.Michael Kaye
Covington, Louisiana, United States
Dr. Max Weisfeld
Baltimore, Maryland, United States
Dr. Linda Stein-Gold
Detroit, Michigan, United States
...and 13 more locations